Información del artículo
La neuropatía es una complicación frecuente de la diabetes mellitus. Un porcentaje significativo de los pacientes con neuropatía diabética presenta dolor neuropático crónico con impacto en el paciente y su calidad de vida. La pregabalina es un fármaco con actividad antiepiléptica, analgésica y ansiolítica del que se ha demostrado utilidad en el tratamiento del dolor neuropático periférico. En el presente artículo se revisan sus propiedades farmacológicas y la evidencia científica que justifica la utilidad de la pregabalina en el tratamiento de la neuropatía diabética dolorosa.
Palabras clave:
Pregabalina
Neuropatía diabética
Dolor neuropático
Neuropathy is a frequent complication of diabetes mellitus. A substantial percentage of patients with diabetic polyneuropathy report chronic neuropathic pain with significant impairment of quality of life. Pregabalin is a drug with antiepileptic, analgesic and anxiolytic activity, which has been demonstrated to be useful in the treatment of peripheral neuropathic pain. The present article reviews the pharmacological profile and scientific evidence that justifies the use of this drug in painful diabetic polyneuropathy.
Key words:
Pregabalin
Diabetic neuropathy
Neuropathic pain
El Texto completo está disponible en PDF
Bibliografía
[1.]
A.J. Boulton, F.A. Gries, J.A. Jervell.
Guidelines for the diagnosis and outpatient management of diabetic peripheral neuropathy.
Diabet Med, 15 (1998), pp. 508-514
[2.]
M.J. Young, A.J. Boulton, A.F. McLeod, D.R.R. Williams, P.H. Sonksen.
A multicentre study of the prevalence of diabetic peripheral neuropathy in the UK hospital clinic population.
Diabetologia, 36 (1993), pp. 150-156
[3.]
J. Cabezas-Cerrato, The prevalence of clinical diabetic polyneuropathy in Spain: a study in primary care and hospital clinic groups.
Neuropathy Spanish Study Group of the Spanish Diabetes Society (SDS).
Diabetologia, 41 (1998), pp. 1263-1269
[4.]
DCCT Research Group.
The effect of intensive diabetes therapy on the development and progression of neuropathy.
Ann Intern Med, 122 (1995), pp. 561-568
[5.]
UKPDS.
Intensive blood glucose with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes.
Lancet, 352 (1998), pp. 837-853
[6.]
S. Tesfaye, N. Chaturvedi, S.E. Eaton, J.D. Ward, C. Manes, C. Ionescu-Tirgoviste, EURODIAB Prospective Complications Study Group, et al.
Vascular risk factors and diabetic neuropathy.
N Engl J Med, 352 (2005), pp. 341-350
[7.]
A. Gordois, P. Scuffham, A. Shearer, A. Oglesby, J. Ash Tobian.
The health care costs of diabetic peripheral neuropathy in the U.S..
Diabetes Care, 26 (2003), pp. 1790-1795
[8.]
H. Merskey, N. Bogduk.
Classification of Chronic Pain.
International Association for the Study of Pain, IASP Press, (2002),
[9.]
A.J. Boulton, G. Knight, J. Drury, J.D. Ward.
The prevalence of symptomatic, diabetic neuropathy in an insulin-treated population.
Diabetes Care, 8 (1985), pp. 125-128
[10.]
L. Sorensen, L. Molyneaux, D.K. Yue.
Insensate versus painful diabetic neuropathy: the effects of height, gender, ethnicity and glycaemic control.
Diab Res Clin Pract, 57 (2002), pp. 45-51
[11.]
M.I. Harris, R. Eastman, C. Cowie.
Symptoms of sensory neuropathy in adults with NIDDM in the U.S. population.
Diabetes Care, 16 (1993), pp. 1446-1452
[12.]
B.S. Galer, A. Gianas, M.P. Jensen.
Painful diabetic polyneuropathy: epidemilogy, pain description, and quality of life.
Diab Res Clin Pract, 47 (2000), pp. 123-128
[13.]
A.J. Boulton, A.I. Vinik, J.C. Arezzo, V. Bril, E.L. Feldman, R. Freeman, et al.
Diabetic neuropathies: a statement by the American Diabetes Association.
Diabetes Care, 28 (2005), pp. 956-962
[14.]
S.M. Stahl.
Mechanism of action of alpha2delta ligands: voltage sensitive calcium channel (VSCC) modulators.
J Clin Psychiatry, 65 (2004), pp. 1033-1034
[15.]
C.P. Taylor.
The biology and pharmacology of calcium channel alpha2-delta proteins Pfizer Satellite Symposium to the 2003 Society for Neuroscience Meeting. Sheraton New Orleans Hotel, New Orleans, LA November 10, 2003.
CNS Drug Rev, 10 (2004), pp. 183-188
[16.]
E. Ben-Menachem.
Pregabalin pharmacology and its relevance to clinical practice.
Epilepsia, 45 (2004), pp. 13-18
[17.]
M. Bialer, S.I. Johannessen, H.J. Kupferberg, R.H. Levy, E. Perucca, T. Tomson.
Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII).
Epilepsy Res, 61 (2004), pp. 1-48
[18.]
E.J. Randinitis, E.L. Posvar, C.W. Alvey, A.J. Sedman, J.A. Cook, H.N. Bockbrader.
Pharmacokinetics of pregabalin in subjects with various degrees of renal function.
J Clin Pharmacol, 43 (2003), pp. 277-283
[19.]
M.J. Brodie, E.A. Wilson, D.L. Wesche, C.W. Alvey, E.J. Randinitis, E.L. Posvar, et al.
Pregabalin drug interaction studies: lack of effect on the pharmacokinetics of carbamazepine, phenytoin, lamotrigine, and valproate in patients with partial epilepsy.
Epilepsia, 46 (2005), pp. 1407-1413
[20.]
B. Corrigan, P. Burger, H. Bockbrader.
Population pharmacokinetics of pregabalin in healthy volunteers, renally impaired patients and patients with chronic pain.
J Pain, 3 (2002), pp. 47
[21.]
J.F. Horga de la Parte, A. Horga.
Pregabalina. Aportaciones de los ligandos α2δ de canales de calcio en el tratamiento de la epilepsia y el dolor neuropático.
Rev Neurol, 42 (2006), pp. 223-237
[22.]
R.W. Richter, R. Portenoy, U. Sharma, L. Lamoreaux, H. Bockbrader, L.E. Knapp.
Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial.
J Pain, 6 (2005), pp. 253-260
[23.]
H. Lesser, U. Sharma, L. Lamoreaux, R.M. Poole.
Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial.
Neurology, 63 (2004), pp. 2104-2110
[24.]
J. Rosenstock, M. Tuchman, L. Lamoreaux, U. Sharma.
Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial.
Pain, 110 (2004), pp. 628-638
[25.]
T. Toelle, M. Versavel, C. Glessner.
A novel treatment for diabetic peripheral neuropathy: Pregabalin dose and pain relief [resumen].
Anesthesiology, 101 (2004), pp. A967
[26.]
R. Freynhagen, K. Strojek, T. Griesing, E. Whalen, M. Balkenohl.
Efficacy of pregabalin in neuropathic pain evaluated in a 12- week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens.
Pain, 115 (2005), pp. 254-263
[28.]
J.T. Farrar, J.P. Young, L. LaMoreaux, J.L. Werth, M. Poole.
Clinical importance of changes in chronic pain intensity measured on a 11-point numerical pain rating scale.
Pain, 94 (2001), pp. 149-158
[29.]
J.E. Ware, C.D. Sherbourne.
The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.
Med Care, 30 (1992), pp. 473-483
[30.]
D.M. McNair, M. Lorr, L.F. Droppleman.
POMS: Profile of Mood States.
Multi-Health Systems, (1992),
[31.]
J.E. Frampton, R.H. Foster.
Pregabalin in the treatment of postherpetic neuralgia.
Drugs, 65 (2005), pp. 111-118
[32.]
R.K. Portenoy, U. Sharma, J. Young, L. LaMoreaux, K. Chartier.
Pregabalin sustains its efficacy as long-term maintenance therapy for neuropathic pain associated with diabetic neuropathy and postherpetic neuralgia [resumen].
Diabetes, 53 (2004), pp. A142
[33.]
E. D’Urso De Cruz, R.H. Dworkin, B. Stacey, J. Siffert, B. Emir.
Treatment of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia in treatment-refractory patients: Findings from a long-term open-label trial of pregabalin.
Eur J Neurol, 12 (2005), pp. 37
[34.]
A. Vinik.
Use of antiepileptic drugs in the treatment of chronic painful diabetic neuropathy.
J Clin Endocrinol Metab, 90 (2005), pp. 4936-4945
[35.]
Ficha técnica de pregabalina (Lyrica); 2006.
[36.]
M.B. Max, M. Culnane, S.C. Schafer, R.H. Gracely, D.J. Walther, B. Smoller, et al.
Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood.
Neurology, 37 (1987), pp. 589-596
[37.]
M.B. Max, S.A. Lynch, J. Muir, S.E. Shoaf, B. Smoller, R. Dubner.
Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy.
N Engl J Med, 326 (1992), pp. 1250-1256
[38.]
C. Dallocchio, C. Buffa, P. Mazzarello, S. Chiroli.
Gabapentin vs. amitriptyline in painful diabetic neuropathy: an open-label pilot study.
J Pain Symptom Manage, 20 (2000), pp. 280-285
[39.]
M. Vrethem, J. Boivie, H. Arnqvist.
A comparison of amitryptiline and maprotiline in the treatment of painful polyneuropathy in diabetics and nondiabetics.
Clin J Pain, 13 (1997), pp. 313-323
[40.]
F. Blasco Patiño, J. Martínez López de Letona, P. Villares, A.I. Jiménez.
El paciente anciano polimedicado: efectos sobre su salud y sobre el sistema sanitario.
Inf Ter Sist Nac Salud, 29 (2005), pp. 152-162
[41.]
R.D. Elwes, C.D. Binnie.
Clinical pharmacokinetics of newer antiepileptic drugs. Lamotrigine, vigabatrin, gabapentin and oxcarbazepine.
Clin Pharmacokinet, 30 (1996), pp. 403-415
[42.]
A. Sabers, L. Gram.
Newer anticonvulsants: comparative review of drug interactions and adverse effects.
Drugs, 60 (2000), pp. 23-33
[43.]
G. Hussein, A.S. Troupin, G. Montouris.
Gabapentin interaction with felbamate.
Neurology, 47 (1996), pp. 1106
[44.]
J. González-Escalada, M. Rodríguez, J. Rejas, M. Vera-Llonch, E. Dukes.
Model-based evaluation of the cost-effectiveness of pregabalin versus gabapentin in patients with painful diabetic polyneuropathy and postherpetic neuralgia: a Spanish perspective.
Rev Esp Soc Dolor, 12 (2005), pp. 63-64
[45.]
J. Raskin, Y.L. Pritchett, F. Wang, D.N. D'Souza, A.L. Waninger, S. Iyengar, et al.
A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain.
Pain Med, 6 (2005), pp. 346-356
[46.]
D.J. Goldstein, Y. Lu, M.J. Detke, T.C. Lee, S. Iyengar.
Duloxetine vs. placebo in patients with painful diabetic neuropathy.
Pain, 116 (2005), pp. 109-118
Copyright © 2007. Sociedad Española de Endocrinología y Nutrición
